SCHEMBL649071

SCHEMBL649071

O=C(O)CCC(=O)Nc1ncc(C=C2SC(=Nc3ccc(Cl)cc3Cl)NC2=O)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 2/20 0.44
CDC25B P30305 2/20 0.44
RNASEL Q05823 1/20 0.43
GSK3B P49841 2/20 0.42
DYRK3 O43781 3/20 0.40
PTPN7 P35236 1/20 0.39
DUSP3 P51452 1/20 0.39
PTPN12 Q05209 1/20 0.39
PTPN22 Q9Y2R2 1/20 0.39
HSD11B1 P28845 1/20 0.38
KIF11 P52732 1/20 0.38
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
PIM1 P11309 1/20 0.37
PTPN11 Q06124 1/20 0.36
MMP3 P08254 1/20 0.36
CSNK1E P49674 1/20 0.36
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649070 1.00 CDC25A (0.44) CDC25ACDC25BRNASELGSK3BDYRK3
SCHEMBL652059 0.91 RNASEL (0.40) CDC25ACDC25BRNASELGSK3BDYRK3
SCHEMBL651036 0.91 RNASEL (0.40) CDC25ACDC25BRNASELGSK3BDYRK3
SCHEMBL648560 0.87 CDC25A (0.44) CDC25ACDC25BRNASELGSK3BDYRK3
SCHEMBL649992 0.87 CDC25A (0.44) CDC25ACDC25BRNASELGSK3BDYRK3
SCHEMBL650338 0.86 KMT2A (0.50) CDC25ACDC25BPTPN7DUSP3PTPN12
SCHEMBL650337 0.86 KMT2A (0.50) CDC25ACDC25BPTPN7DUSP3PTPN12
SCHEMBL651164 0.86 MAPT (0.52) RNASELMEN1POLBKMT2AALOX15
SCHEMBL651165 0.86 MAPT (0.52) RNASELMEN1POLBKMT2AALOX15
SCHEMBL649993 0.85 RNASEL (0.43) CDC25ACDC25BRNASELGSK3BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 CDC25A 78/4885CDC25B 59/4885RNASEL 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.